Hyemin Kim
Research Subjects
Research Interests
Hyemin Kim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bo-Reum Kim
The Catholic University of Korea 1 Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine Seoul, Republic of Korea
13 shared publications - Byung-Sik Cho
Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
13 shared publications - Daehun Kwag
Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
13 shared publications - Hadong Kim
Pin Therapeutics, Seongnam-si, Republic of Korea
13 shared publications - Hee-Je Kim
17Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
13 shared publications - Hoon Choi
Pin Therapeutics, Seongnam-si, Republic of Korea
13 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models. PinA1 preferentially degraded CK1α at nanomolar concentrations, resulting in enhanced p53 expression, cell-cycle arrest, and apoptosis in TP53 wild-type AML cell lines but not in TP53-mutated cells. PinA1 also induced CK1α degradation and p53-dependent apoptosis in primary AML cells with wild-type TP53. Notably, PinA1 had minimal effects on the viability of human peripheral blood and bone marrow mononuclear cells, including CD34+ cells, with limited activation of the p53 pathway. In both cell lines and primary AML cells, PinA1 enhanced apoptosis when combined with targeted agents, including FLT3, BCL-2, or MDM2 inhibitors. PinA1 demonstrated robust antileukemic efficacy as a monotherapy and exhibited synergistic effects when combined with targeted agents in xenografts derived from human AML cell lines and primary AML cells. In conclusion, PinA1 degrades CK1α, activates the p53 pathway, and induces cell-cycle arrest and apoptosis in TP53 wild-type AML cells. The robust antileukemic efficacy of PinA1, both as monotherapy and further in combination with targeted agents, along with its minimal toxicity to normal hematopoietic cells, underscores its potential for future clinical applications. Significance:PinA1 is a selective molecular glue degrader of CK1α that activates p53 signaling, induces apoptosis in TP53 wild-type acute myeloid leukemia, spares normal hematopoietic cells, and shows strong synergy with targeted therapies.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Casein kinase 1α (CK1α) is a multifunctional serine/threonine kinase, serving as an upstream regulator of the p53 pathway and a potential therapeutic target for acute myeloid leukemia (AML). Small-molecule degraders show preclinical promise in AML by selectively degrading target proteins. In this study, we developed and evaluated PinA1, a molecular glue degrader targeting CK1α, in preclinical AML models. PinA1 preferentially degraded CK1α at nanomolar concentrations, resulting in enhanced p53 expression, cell-cycle arrest, and apoptosis in TP53 wild-type AML cell lines but not in TP53-mutated cells. PinA1 also induced CK1α degradation and p53-dependent apoptosis in primary AML cells with wild-type TP53. Notably, PinA1 had minimal effects on the viability of human peripheral blood and bone marrow mononuclear cells, including CD34+ cells, with limited activation of the p53 pathway. In both cell lines and primary AML cells, PinA1 enhanced apoptosis when combined with targeted agents, including FLT3, BCL-2, or MDM2 inhibitors. PinA1 demonstrated robust antileukemic efficacy as a monotherapy and exhibited synergistic effects when combined with targeted agents in xenografts derived from human AML cell lines and primary AML cells. In conclusion, PinA1 degrades CK1α, activates the p53 pathway, and induces cell-cycle arrest and apoptosis in TP53 wild-type AML cells. The robust antileukemic efficacy of PinA1, both as monotherapy and further in combination with targeted agents, along with its minimal toxicity to normal hematopoietic cells, underscores its potential for future clinical applications. Significance:PinA1 is a selective molecular glue degrader of CK1α that activates p53 signaling, induces apoptosis in TP53 wild-type acute myeloid leukemia, spares normal hematopoietic cells, and shows strong synergy with targeted therapies.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
The scheme for the procedure of AML cell line-derived xenograft models.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
The scheme for the procedure of AML cell line-derived xenograft models.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Figure S1 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Figure S1 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 induces anti-leukemia effects as monotherapy and enhances efficacy in combination with gilteritinib in xenografts from primary FLT3-ITD mutated AML.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 induces anti-leukemia effects as monotherapy and enhances efficacy in combination with gilteritinib in xenografts from primary FLT3-ITD mutated AML.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
CK1α degradation and p21 induction in tumor tissues following PinA1 treatment in MV4-11 xenograft models.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
CK1α degradation and p21 induction in tumor tissues following PinA1 treatment in MV4-11 xenograft models.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 induces CK1α degradation and selectively activates the p53 signaling pathway in TP53 wild-type AML cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 induces CK1α degradation and selectively activates the p53 signaling pathway in TP53 wild-type AML cells.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 selectivity for CK1α degradation and CRBN dependency.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 selectivity for CK1α degradation and CRBN dependency.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 improves anti-leukemia effects when used in combination with targeted agents ex vivo.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
PinA1 improves anti-leukemia effects when used in combination with targeted agents ex vivo.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Cell-cycle analysis in AML cell lines following PinA1 treatment.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Cell-cycle analysis in AML cell lines following PinA1 treatment.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Effect of PinA1 on apoptosis in AML cells.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells
Effect of PinA1 on apoptosis in AML cells.